Disruption of metabolic homeostasis in AML cells, induction of ROS production and ATF4. Inhibition of CPT1a and subsequent sensitization of AML cells to cytarabine. Induction of an energetic shift towards low OXPHOS and increase in anti-leukemia effects of cytarabine. The gene discussed is CPT1A; the disease is acute myeloid leukemia.